BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 2014; 20(26): 8407-8415 [PMID: 25024598 DOI: 10.3748/wjg.v20.i26.8407] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 周赛君, 于德民, 于珮. 糖尿病非酒精性脂肪肝防治新进展. 世界华人消化杂志 2015; 23(32): 5113-5122 [DOI: 10.11569/wcjd.v23.i32.5113] [Reference Citation Analysis]
2 Sá C, Oliveira AR, Machado C, Azevedo M, Pereira-Wilson C. Effects on Liver Lipid Metabolism of the Naturally Occurring Dietary Flavone Luteolin-7-glucoside. Evid Based Complement Alternat Med 2015;2015:647832. [PMID: 26113868 DOI: 10.1155/2015/647832] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
3 Morlán-Coarasa MJ, Arias-Loste MT, Ortiz-García de la Foz V, Martínez-García O, Alonso-Martín C, Crespo J, Romero-Gómez M, Fábrega E, Crespo-Facorro B. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology (Berl) 2016;233:3947-52. [PMID: 27620899 DOI: 10.1007/s00213-016-4422-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
4 Nogami A, Yoneda M, Kobayashi T, Kessoku T, Honda Y, Ogawa Y, Suzuki K, Tomeno W, Imajo K, Kirikoshi H, Koide T, Fujikawa H, Saito S, Nakajima A. Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. Hepatol Res 2019;49:872-80. [PMID: 30974498 DOI: 10.1111/hepr.13349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
5 Tan HL, Chan KG, Pusparajah P, Duangjai A, Saokaew S, Mehmood Khan T, Lee LH, Goh BH. Rhizoma Coptidis: A Potential Cardiovascular Protective Agent. Front Pharmacol 2016;7:362. [PMID: 27774066 DOI: 10.3389/fphar.2016.00362] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 9.8] [Reference Citation Analysis]
6 Mikolasevic I, Milic S, Turk Wensveen T, Grgic I, Jakopcic I, Stimac D, Wensveen F, Orlic L. Nonalcoholic fatty liver disease - A multisystem disease? World J Gastroenterol 2016; 22(43): 9488-9505 [PMID: 27920470 DOI: 10.3748/wjg.v22.i43.9488] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 85] [Article Influence: 18.2] [Reference Citation Analysis]
7 Martins E, Oliveira A. NAFLD and cardiovascular disease. Porto Biomed J 2018;3:e2. [PMID: 31595238 DOI: 10.1016/j.pbj.0000000000000002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Brand T, van den Munckhof ICL, van der Graaf M, Schraa K, Dekker HM, Joosten LAB, Netea MG, Riksen NP, de Graaf J, Rutten JHW. Superficial vs Deep Subcutaneous Adipose Tissue: Sex-Specific Associations With Hepatic Steatosis and Metabolic Traits. J Clin Endocrinol Metab 2021;106:e3881-9. [PMID: 34137897 DOI: 10.1210/clinem/dgab426] [Reference Citation Analysis]
9 Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-6834 [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 80] [Article Influence: 14.7] [Reference Citation Analysis]
10 Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla VM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr. 2017;11 Suppl 1:S209-S216. [PMID: 28017631 DOI: 10.1016/j.dsx.2016.12.033] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 13.0] [Reference Citation Analysis]
11 Sun DQ, Liu WY, Wu SJ, Zhu GQ, Braddock M, Zhang DC, Shi KQ, Song D, Zheng MH. Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. Oncotarget 2016;7:5728-37. [PMID: 26735337 DOI: 10.18632/oncotarget.6799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
12 Viglino D, Martin M, Almeras N, Després JP, Coxson HO, Pépin JL, Vivodtzev I, Maltais F; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis. Int J Chron Obstruct Pulmon Dis 2019;14:3053-61. [PMID: 32099343 DOI: 10.2147/COPD.S233834] [Reference Citation Analysis]
13 Kim J, Lee DY, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation. PLoS One 2017;12:e0180118. [PMID: 28686633 DOI: 10.1371/journal.pone.0180118] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ciavarella A, Gnocchi D, Custodero C, Lenato GM, Fiore G, Sabbà C, Mazzocca A. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thromb Res 2021;198:139-50. [PMID: 33340925 DOI: 10.1016/j.thromres.2020.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wray CL. Advances in the Anesthetic Management of Solid Organ Transplantation. Advances in Anesthesia 2017;35:95-117. [DOI: 10.1016/j.aan.2017.07.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol 2020;19:134-44. [PMID: 31606352 DOI: 10.1016/j.aohep.2019.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
17 Zhang QQ, Lu LG. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol 2015;3:78-84. [PMID: 26357637 DOI: 10.14218/JCTH.2014.00037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
18 Takeuchi M, Takino J, Sakasai-Sakai A, Takata T, Ueda T, Tsutsumi M, Hyogo H, Yamagishi S. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol. 2014;6:880-893. [PMID: 25544875 DOI: 10.4254/wjh.6.i12.880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Wu R, Hou F, Wang X, Zhou Y, Sun K, Wang Y, Liu H, Wu J, Zhao R, Hu J. Nonalcoholic Fatty Liver Disease and Coronary Artery Calcification in a Northern Chinese Population: a Cross Sectional Study. Sci Rep 2017;7:9933. [PMID: 28855585 DOI: 10.1038/s41598-017-09851-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
20 Crespo-Facorro B, Pelayo-Teran JM, Mayoral-van Son J. Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. Neurol Ther 2016;5:105-30. [PMID: 27553839 DOI: 10.1007/s40120-016-0050-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
21 El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Relationship between Heart Disease and Liver Disease: A Two-Way Street. Cells 2020;9:E567. [PMID: 32121065 DOI: 10.3390/cells9030567] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
22 Zhou Y, Lai C, Peng C, Chen M, Li B, Wang X, Sun J, Sun C. Nonalcoholic fatty liver disease as a predictor of atrial fibrillation: a systematic review and meta-analysis. Postepy Kardiol Interwencyjnej 2017;13:250-7. [PMID: 29056998 DOI: 10.5114/aic.2017.70198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Stevanović J, Beleza J, Coxito P, Ascensão A, Magalhães J. Physical exercise and liver "fitness": Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease. Mol Metab 2020;32:1-14. [PMID: 32029220 DOI: 10.1016/j.molmet.2019.11.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
24 Chandrasekharan K, Alazawi W. Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy? Front Pharmacol 2019;10:1413. [PMID: 31969816 DOI: 10.3389/fphar.2019.01413] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
25 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
26 Käräjämäki AJ, Bloigu R, Kauma H, Kesäniemi YA, Koivurova OP, Perkiömäki J, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes. Metabolism. 2016;. [PMID: 27423871 DOI: 10.1016/j.metabol.2016.06.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
27 Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res 2020;90:279-89. [PMID: 30789808 DOI: 10.1024/0300-9831/a000528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
28 Liu Q, Liu SS, Zhao ZZ, Zhao BT, Du SX, Jin WW, Xin YN. TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population. Lipids Health Dis 2019;18:165. [PMID: 31470861 DOI: 10.1186/s12944-019-1108-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
29 Stolic RV, Trajkovic GZ, Kostic MM, Sovtic SR, Odalovic AM, Krdzic BD, Sipic MV, Lazic S, Sojevic-Timotijevic ZN. Correlation between nonalcoholic fatty liver and cardiovascular disease in elderly hemodialysis patients. Int Urol Nephrol 2016;48:883-9. [PMID: 26905407 DOI: 10.1007/s11255-016-1237-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
30 Takeuchi M, Takino JI, Sakasai-Sakai A, Takata T, Ueda T, Tsutsumi M, Hyogo H, Yamagishi SI. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol 2014; 6(12): 880-893 [PMID: 25544875 DOI: 10.4254/wjh.v6.i12.880] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
31 Zheng R, Du Z, Wang M, Mao Y, Mao W. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis 2018;17:262. [PMID: 30458848 DOI: 10.1186/s12944-018-0913-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
32 Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS One. 2015;10:e0142937. [PMID: 26571029 DOI: 10.1371/journal.pone.0142937] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 10.8] [Reference Citation Analysis]
33 Sharifi N, Amani R, Hajiani E, Cheraghian B. Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Exp Biol Med (Maywood) 2016;241:830-8. [PMID: 26811103 DOI: 10.1177/1535370216629009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
34 Hörist-kollmann S, Strametz-juranek J. Female Dietary Patterns and the Pathogenesis of NAFLD. Gender and the Genome 2018;2:49-55. [DOI: 10.1177/2470289718787091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 18.5] [Reference Citation Analysis]
36 Mousavi SN, Faghihi A, Motaghinejad M, Shiasi M, Imanparast F, Amiri HL, Shidfar F. Zinc and Selenium Co-supplementation Reduces Some Lipid Peroxidation and Angiogenesis Markers in a Rat Model of NAFLD-Fed High Fat Diet. Biol Trace Elem Res 2018;181:288-95. [PMID: 28577233 DOI: 10.1007/s12011-017-1059-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
37 Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol 2018;31:296-304. [PMID: 29720855 DOI: 10.20524/aog.2018.0248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 刘娜, 穆华, 郑吉敏, 梁传栋. 去甲肾上腺素各受体亚型在非酒精性脂肪肝大鼠肝组织的表达. 世界华人消化杂志 2016; 24(6): 909-914 [DOI: 10.11569/wcjd.v24.i6.909] [Reference Citation Analysis]
39 Sharma DL, Lakhani HV, Klug RL, Snoad B, El-Hamdani R, Shapiro JI, Sodhi K. Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis. J Clin Cell Immunol 2017;8:523. [PMID: 29177105 DOI: 10.4172/2155-9899.1000523] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
40 Lovric A, Granér M, Bjornson E, Arif M, Benfeitas R, Nyman K, Ståhlman M, Pentikäinen MO, Lundbom J, Hakkarainen A, Sirén R, Nieminen MS, Lundbom N, Lauerma K, Taskinen MR, Mardinoglu A, Boren J. Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. Sci Rep 2018;8:14200. [PMID: 30242179 DOI: 10.1038/s41598-018-31865-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
41 Lee JE, Lee YJ, Chung SY, Cho HW, Park BJ, Jung DH. Severity of nonalcoholic fatty liver disease is associated with subclinical cerebro-cardiovascular atherosclerosis risk in Korean men. PLoS One 2018;13:e0193191. [PMID: 29565984 DOI: 10.1371/journal.pone.0193191] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
42 Yin S, Fan Y, Zhang H, Zhao Z, Hao Y, Li J, Sun C, Yang J, Yang Z, Yang X, Lu J, Xi JJ. Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis. Nat Commun 2016;7:11012. [PMID: 26987776 DOI: 10.1038/ncomms11012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
43 Sun DQ, Wu SJ, Liu WY, Wang LR, Chen YR, Zhang DC, Braddock M, Shi KQ, Song D, Zheng MH. Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. BMJ Open 2016;6:e013781. [PMID: 27927668 DOI: 10.1136/bmjopen-2016-013781] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
44 Gentili A, Daviddi G, De Vuono S, Ricci MA, Di Filippo F, Alaeddin A, Mannarino MR, Boni M, Vaudo G, Lupattelli G. Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. Dig Liver Dis 2016;48:904-8. [PMID: 27160697 DOI: 10.1016/j.dld.2016.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019;34:449-57. [DOI: 10.1093/ndt/gfx381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
46 Klisic A, Kavaric N, Jovanovic M, Soldatovic I, Gligorovic-Barhanovic N, Kotur-Stevuljevic J. Bioavailable testosterone is independently associated with Fatty Liver Index in postmenopausal women. Arch Med Sci 2017;13:1188-96. [PMID: 28883861 DOI: 10.5114/aoms.2017.68972] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
47 Liu L, Yu Y, Zhao M, Zheng D, Zhang X, Guan Q, Xu C, Gao L, Zhao J, Zhang H. Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients. Int J Endocrinol 2017;2017:5753039. [PMID: 28473851 DOI: 10.1155/2017/5753039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
48 Lian K, Feng YN, Li R, Liu HL, Han P, Zhou L, Li CX, Wang Q. Middle- and high-molecular weight adiponectin levels in relation to nonalcoholic fatty liver disease. J Clin Lab Anal 2020;34:e23148. [PMID: 31880002 DOI: 10.1002/jcla.23148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Kang YM, Jung CH, Cho YK, Lee SE, Lee MJ, Hwang JY, Kim EH, Park JY, Lee WJ, Kim HK. Fatty liver disease determines the progression of coronary artery calcification in a metabolically healthy obese population. PLoS One 2017;12:e0175762. [PMID: 28419118 DOI: 10.1371/journal.pone.0175762] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
50 Wang Y, Zeng Y, Lin C, Chen Z. Hypertension and non-alcoholic fatty liver disease proven by transient elastography: Hypertension and NAFLD. Hepatol Res 2016;46:1304-10. [DOI: 10.1111/hepr.12688] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
51 Xu H, Zhuang X. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. Neuropsychiatr Dis Treat 2019;15:2087-99. [PMID: 31413575 DOI: 10.2147/NDT.S208061] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
52 Klisic A, Kavaric N, Ninic A. Predictive Values of Serum Uric Acid and Alanine-aminotransferase for Fatty Liver Index in Montenegrin Population. J Med Biochem. 2019;38:407-417. [PMID: 31496904 DOI: 10.2478/jomb-2019-0001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
53 Jayakumar S, Harrison SA, Loomba R. Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep 2016;15:86-95. [PMID: 27795938 DOI: 10.1007/s11901-016-0296-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
54 Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, Vilsbøll T. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166125. [PMID: 27835680 DOI: 10.1371/journal.pone.0166125] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 20.6] [Reference Citation Analysis]
55 Jaruvongvanich V, Wirunsawanya K, Sanguankeo A, Upala S. Nonalcoholic fatty liver disease is associated with coronary artery calcification: A systematic review and meta-analysis. Dig Liver Dis 2016;48:1410-7. [PMID: 27697419 DOI: 10.1016/j.dld.2016.09.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
56 Yuan G, Xu M, Tan M, Dong J, Chen X. Supplementation with Docosahexaenoic Acid and Vitamin E Improves Hepatic Triglyceride Accumulation Induced by High‐Fat Diet in Mice. Eur J Lipid Sci Technol 2021;123:2000224. [DOI: 10.1002/ejlt.202000224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]